Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



From the monthly archives: February, 2017

We are pleased to present below all posts archived in 'February, 2017'. If you still can't find what you are looking for, try using the search box.

Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial Results

UK & Marlborough, USA – Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced fourth quarter and full year 2016 financial results.

Read the rest of entry »

Cell Lines & Media for Difficult to Culture Tumor Types

AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumor types where no models may exist.

Read the rest of entry »

Caldan Therapeutics Announces Key Appointment

 Edinburgh, UK – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH), is pleased to announce the appointment of Dr Mark Payton as Chief Executive Officer (CEO).

Read the rest of entry »

Oxford Immunotec to Present at the Cowen and Company 37th Annual Health Care Conference

OXFORD, United Kingdom and MARLBOROUGH, Mass., February 22, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017, at 3:20 p.m. EST at the Boston Marriott Copley Place in Boston.

Read the rest of entry »

SRG 2017 Salary Survey now available

The latest figures, the deepest insights, the most comprehensive expertise.

Read the rest of entry »

Reach Separations Turns 5!

February the 13th saw Reach Separations celebrate five years of laboratory occupation at Biocity Nottingham!

Read the rest of entry »

Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017

OXFORD, United Kingdom and MARLBOROUGH, Mass., February 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release fourth quarter and full year 2016 financial results after the close of the market on Tuesday, February 28, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 5:00 p.m. Eastern Time the same day. The call will be concurrently webcast.

Read the rest of entry »

NIHR Brain Injury Healthcare Technology Co-operative – Seedcorn Funding Competition 2016/2017 – FUNDING CALL ROUND 2 NOW OPEN

The NIHR Brain Injury Healthcare Technology Co-operative is pleased to announce the second round of its second national competition. The seed funding call (up to £10,000) is for the early development of novel technology-based solutions applicable to the brain injury pathway, from prevention of injury all the way through to technologies for independent living.  Applications are invited from academic institutions, NHS Trusts, third sector organisations and SME’s.

Read the rest of entry »

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

Oxford, UK & San Jose, USA - Oxford BioTherapeutics (“OBT”), an international biotechnology company developing clinical stage antibody therapeutics for cancer, today announced a significant strengthening of its oncology focused Board of Directors with the appointment of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as a non-executive director, joining Glenn Begley, Shawn Tomasello, Tom Bradley and Christian Rohlff.

Read the rest of entry »

Contractor appointed for £13 million landmark Oxford scheme

Oxford, UK - The Oxford Science Park has awarded a £13 million design and build contract for Plot 12, a new state of the art office building, capable of housing laboratories, and with roof terrace, comprising 61,500 sq ft (5,713 sq m), to Barnwood Construction Ltd.

Read the rest of entry »

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

Future Blends are looking for an OBN member company who could help them strip solvent from one of their process streams. Initially looking at a 1 tonne scale. If you can help, or know of someone who might be able to then please contact Shane O’Leary at Future Blends. soleary@futureblends.com.

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.